RenovaCare Awarded U.S. Patent For SkinGun™ Device To Spray Stem Cells On To Wounds

NEW YORK & PITTSBURGH–(BUSINESS WIRE)– RenovaCare, Inc., (RCAR), developer of the patented CellMist™ and
SkinGun™ technologies* for isolating and spraying a patient’s own stem
cells onto burns and wounds for rapid self-healing, today announced that
the company has bolstered its patent portfolio with the issuance of a
United States patent for its novel SkinGun™ device. The United States
Patent and Trademark Office has granted an additional 30-month extension
for the patent, providing protection beyond the year 2035.

This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20161206005236/en/

RenovaCare President and CEO, Thomas Bold, holds patented stem cell spray device, SkinGun (Photo: Business Wire)

The issuance of the United States patent reinforces the company’s
current patent protections in Germany.

“This formal intellectual property strengthens our competitive position
in the marketplace and supports our long-standing conviction that our
technology is a novel therapeutic medical device for isolating and
spraying human stem cells on to serious burns and wounds,” said Thomas
Bold, President and CEO of RenovaCare, Inc.

These RenovaCare patents provide exclusive rights for its SkinGun™
device, including the exclusion of other developers from making,
copying, using, or selling the invention unless they have obtained a
license to do so.

This announcement comes on the heels of world-leading expert in the
isolation of specific stem cells ideal for spraying onto burns and
wounds, Dr. Roger Esteban-Vives, joining the company as Director of Cell
Sciences.

Independent test results conducted by one of the world’s largest
university hospitals show that RenovaCare SkinGun™ achieves the ‘gold
standard’ when it comes to viability for skin regeneration. Cell
viability is essential to regenerating skin for burns, wounds, and
cosmetic applications. Data confirmed that human skin stem cells sprayed
with the company’s patented SkinGun™ maintained 97.3% viability.

*RenovaCare products are currently in development and are not available
for sale in the United States.

About RenovaCare

RenovaCare, Inc. is developing first-of-its-kind autologous
(self-donated) stem cell therapies for the regeneration of human organs.
Its initial product under development targets the body’s largest organ,
the skin. The company’s flagship technology, the CellMist™ System, uses
its patented SkinGun™ to spray a liquid suspension of a patient’s stem
cells – the CellMist™ Solution – onto wounds. RenovaCare is developing
its CellMist™ System as a promising new alternative for patients
suffering from burns, chronic and acute wounds, and scars. In the US
alone, this $45 billion market is greater than the spending on
high-blood pressure management, cholesterol treatments, and back pain
therapeutics.

For additional information, please call Drew Danielson at: 888-398-0202
or visit:
http://renovacareinc.com

To receive future press releases via email, please visit:
http://renovacareinc.com/investors/register/

Follow us on Twitter https://twitter.com/Renovacareinc
or follow us on Facebook https://www.facebook.com/renovacarercar

For answers to frequently asked questions, please visit our FAQ’s page:
http://renovacareinc.com/investors/faqs/

Social Media Disclaimer

Investors and others should note that we announce material financial
information to our investors using SEC filings and press releases. We
use our website and social media to communicate with our subscribers,
shareholders and the public about the company, RenovaCare, Inc.
development, and other corporate matters that are in the public domain.
At this time, the company will not post information on social media that
could be deemed to be material information unless that information was
distributed to public distribution channels first. We encourage
investors, the media, and others interested in the company to review the
information we post on the company’s website and the social media
channels listed below:

• Facebook

• Twitter

* This list may be updated from time to time.

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of
an offer for the purchase or sale of any securities. This release
contains forward-looking statements that are based upon current
expectations or beliefs, as well as a number of assumptions about future
events. Although RenovaCare, Inc. (the “Company”) believes that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, it can give no
assurance that such expectations and assumptions will prove to have been
correct. Forward-looking statements, which involve assumptions and
describe our future plans, strategies, and expectations, are generally
identifiable by use of the words “may,” “will,” “should,” “could,”
“expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or
the negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements are
subject to numerous factors and uncertainties, including but not limited
to: the timing and success of clinical and preclinical studies of
product candidates, the potential timing and success of the Company’s
product programs through their individual product development and
regulatory approval processes, adverse economic conditions, intense
competition, lack of meaningful research results, entry of new
competitors and products, inadequate capital, unexpected costs and
operating deficits, increases in general and administrative costs,
termination of contracts or agreements, obsolescence of the Company’s
technologies, technical problems with the Company’s research, price
increases for supplies and components, litigation and administrative
proceedings involving the Company, the possible acquisition of new
businesses or technologies that result in operating losses or that do
not perform as anticipated, unanticipated losses, the possible
fluctuation and volatility of the Company’s operating results, financial
condition and stock price, losses incurred in litigating and settling
cases, dilution in the Company’s ownership of its business, adverse
publicity and news coverage, inability to carry out research,
development and commercialization plans, loss or retirement of key
executives and research scientists, and other risks. There can be no
assurance that further research and development will validate and
support the results of our preliminary research and studies. Further,
there can be no assurance that the necessary regulatory approvals will
be obtained or that the Company will be able to develop commercially
viable products on the basis of its technologies. In addition, other
factors that could cause actual results to differ materially are
discussed in the Company’s most recent Form 10-Q and Form 10-K filings
with the Securities and Exchange Commission. These reports and filings
may be inspected and copied at the Public Reference Room maintained by
the U.S. Securities & Exchange Commission at 100 F Street, N.E.,
Washington, D.C. 20549. You can obtain information about operation of
the Public Reference Room by calling the U.S. Securities & Exchange
Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission
also maintains an Internet site that contains reports, proxy and
information statements, and other information regarding issuers that
file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov.
The Company undertakes no obligation to publicly release the results of
any revisions to these forward-looking statements that may be made to
reflect the events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161206005236/en/